» Articles » PMID: 15295608

Analysis of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Comparison Between RQ-PCR Analysis of Ig/TcR Gene Rearrangements and Multicolor Flow Cytometric Immunophenotyping

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2004 Aug 6
PMID 15295608
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Detection of minimal residual disease (MRD) in follow-up samples from patients with ALL is essential for evaluation of treatment response. We applied multicolor flow cytometry and real-time quantitative PCR (RQ-PCR) to compare MRD results in 71 follow-up samples from 22 children treated for ALL. When results obtained by flow cytometry and RQ-PCR were grouped into positive-negative categories, a significant level of agreement was found in 72% of samples (P<0.001). However, if a cutoff level of 0.01% was applied, the concordance was 89%. MRD could be quantified in 19 samples by both methods, showing a strong correlation (P<0.01). Nevertheless, MRD levels differed more than five-fold between both methods in 4/19 samples. In 20 (28%) samples, the two techniques showed discordant results. Most discordant results (17/20) were due to the limited sensitivity of flow cytometry analysis within the range 0.01-0.001%; remaining discordant results were due to the instable or subclonal IG/TCR gene rearrangements or a limited quantitative range of the applied RQ-PCR targets. Although concordant results could be obtained by flow cytometry and RQ-PCR analysis, MRD levels may differ. Therefore, MRD data obtained by these two techniques are not yet easily exchangeable.

Citing Articles

CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.

Cao L, Zhou Y, Gale R, Qin Y, Wu L, Zhao M Biomol Biomed. 2023; 23(6):1079-1088.

PMID: 37183704 PMC: 10655882. DOI: 10.17305/bb.2023.9034.


Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.

Gao Q, Liu Y, Aypar U, Baik J, Londono D, Sun X Cytometry B Clin Cytom. 2023; 104(4):279-293.

PMID: 36999235 PMC: 10508218. DOI: 10.1002/cyto.b.22120.


Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.

Modvig S, Hallbook H, Madsen H, Siitonen S, Rosthoj S, Tierens A Leukemia. 2020; 35(7):1894-1906.

PMID: 33318611 PMC: 8257490. DOI: 10.1038/s41375-020-01100-5.


Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.

Abou Dalle I, Jabbour E, Short N Ther Adv Hematol. 2020; 11:2040620720910023.

PMID: 32215194 PMC: 7065280. DOI: 10.1177/2040620720910023.


Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status.

Rastogi P, Sachdeva M Indian J Hematol Blood Transfus. 2020; 36(1):3-15.

PMID: 32174688 PMC: 7042470. DOI: 10.1007/s12288-019-01118-5.